Feasibility trial of mindfulness-based cognitive therapy (MBCT) follow-up programs for anxiety disorders

Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy (MBCT) follow-up engagement programs for anxiety disorders : a randomised controlled feasibility trial - Effectiveness and cost-effectiveness of MBCT follow-up engagement programs for anxiety disorders : a randomised controlled feasibility trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038626

Enrollment

Registered

2019-11-19

Start date

2019-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders

Interventions

8 weekly sessions of MBCT + 10 monthly follow-up engagement program 8 weekly sessions of MBCT only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: /Diagnosed as panic disorder, agoraphobia, or social anxiety disorder, based on SCID / No improvement after 4 week's TAU /Ability to consent in writing

Exclusion criteria

Exclusion criteria: /Past history of substance related disorders /Alcohol dependence /Drug dependence /Anti social personality disorder /Severe suicidal ideation or self-harm behaviour /Difficult to follow up for 12 months after start of intervention /Dissent to the possibility of being allocated to the control group /Organic brain disorders /Other severe general medical conditions

Design outcomes

Primary

Measure	Time frame
1) enrollment rate, 2) dropout rate, 3)retention rate, 4) mean and standardized deviation of the clinical parameters (STAI) at 5, 8, 12months	—

Secondary

Measure	Time frame
mean and standardized deviation of the following clinical parameters at 5, 8, 12months: Panic disorder severity scale, Mobility inventory, LSAS-J, SF-36, SPANE, RSES, FFMQ, CD-RISC, SCS, QIDS, GAD7, PSS, HPQ, SWLS, FS, MAIA, EQ-5D, HAM-A, interoception, healthcare service usage, medication adherence, adherence to home work etc. Cost effectiveness will be assessed by Incremental Cost Effectiveness Ratio using quality adjusted life years as a clinical parameter.	—

Measure

Time frame

mean and standardized deviation of the following clinical parameters at 5, 8, 12months: Panic disorder severity scale, Mobility inventory, LSAS-J, SF-36, SPANE, RSES, FFMQ, CD-RISC, SCS, QIDS, GAD7, PSS, HPQ, SWLS, FS, MAIA, EQ-5D, HAM-A, interoception, healthcare service usage, medication adherence, adherence to home work etc. Cost effectiveness will be assessed by Incremental Cost Effectiveness Ratio using quality adjusted life years as a clinical parameter.

—

Countries

Japan

Contacts

Public Contactmitsuhiro sado

Keio University School of Medicine Department of Neuropsychiatry

mitsusado@keio.jp+81-(0)3-5363-3971

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026